About: Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
Creator	Simor, Andrew Predy, Gerald Mcelhaney, Janet Mcneil, Shelly Zhirnov, Oleg
topic	covid:648e9c790e9707c35271988c3f86aa147a9eda05#this
Source	Medline; PMC
abstract	CVT-E002 (a proprietary extract) was found to be effective in the prevention of upper respiratory infections (URIs) in healthy adults, and institutionalized and community-dwelling seniors. A multicenter, randomized, double-blind, placebo-controlled trial was carried out to determine effects of CVT-E002 in the prevention of URIs in influenza-vaccinated community-dwelling adults. 783 community-dwelling adults were randomized to receive placebo, 400 mg or 800 mg treatment/d (1 : 1 : 1) for 6 months. Primary analysis on the incidence of laboratory-confirmed-clinical URIs (LCCUs), including influenza A and B, was performed on those receiving at least one dose. Secondary analysis was performed on study completers and included incidence, severity, and duration of URIs meeting a Jackson-based criteria and safety of CVT-E002. The incidence of LCCUs in the ITT group was 5.5%, 5.2%, and 4.6% in the placebo, 400 mg and 800 mg groups, respectively (P = 0.89). Jackson-confirmed URIs were significantly lower in the treated groups (P < 0.04). CVT-E002 supplementation reduced the severity and duration of Jackson-confirmed URIs. The results indicate that CVT-E002 can be safely used by similar groups and may prevent symptoms of URIs; larger sample size is warranted.
has issue date	2011-07-20(xsd:dateTime)
bibo:doi	10.1155/2011/759051
bibo:pmid	23074661
has license	cc-by
sha1sum (hex)	648e9c790e9707c35271988c3f86aa147a9eda05
schema:url	https://doi.org/10.1155/2011/759051
resource representing a document's title	Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
has PubMed Central identifier	PMC3447298
has PubMed identifier	23074661
schema:publication	Influenza Res Treat
resource representing a document's body	covid:648e9c790e9707c35271988c3f86aa147a9eda05#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/648e9c790e9707c35271988c3f86aa147a9eda05
is schema:about of	named entity 'randomized' named entity 'receive' named entity 'double-blind' named entity 'RECEIVE' named entity 'JACKSON' named entity '28A' named entity 'RANDOMIZED' named entity 'GROUPS' named entity 'DETERMINE' named entity 'DWELLING' named entity 'RANDOMIZED' named entity 'LABORATORY' named entity 'ON STUDY' named entity 'CRITERIA' named entity 'UPPER RESPIRATORY INFECTIONS' named entity 'EFFECTS' covid:arg/648e9c790e9707c35271988c3f86aa147a9eda05 named entity 'RESPIRATORY INFECTIONS' named entity 'DWELLING' named entity 'INCIDENCE' named entity 'INSTITUTIONALIZED' named entity 'COMMUNITY' named entity 'DURATION' named entity 'CONFIRMED' named entity '28P' named entity 'INFLUENZA' named entity 'CARRIED' named entity 'PREVENTION OF' named entity 'SAFETY' named entity 'ADULTS' named entity 'INCLUDING' named entity 'VACCINATED' named entity 'HEALTHY' named entity 'EFFICACY' named entity 'CLINICAL STUDY' named entity 'PROPRIETARY' named entity 'ADULTS' named entity 'PLACEBO-CONTROLLED TRIAL' named entity 'DOUBLE' named entity 'VACCINATED' named entity 'SECONDARY' named entity '800' named entity 'ANALYSIS' named entity 'PLACEBO-CONTROLLED TRIAL' named entity 'DOSE' named entity 'RECEIVING' named entity 'GROUP' named entity 'CLINICAL' named entity 'TREATED' named entity 'PROPRIETARY' named entity 'INFLUENZA A' named entity 'EFFECTIVE' named entity 'MEETING' named entity 'LOWER' named entity 'PERFORMED' named entity 'BASED' named entity 'PRIMARY' named entity 'ITT' named entity 'PLACEBO' named entity 'TREATMENT' named entity 'BLIND' named entity 'SAFETY' named entity '0.04' named entity 'DOUBLE' named entity 'EXTRACT' named entity 'CVT-E002' named entity 'SUPPLEMENTATION' named entity '400' named entity 'INFLUENZA' named entity 'FOUND' named entity 'PREVENTION OF' named entity 'SEVERITY' named entity '5.5' named entity 'MONTHS' named entity 'PANAX QUINQUEFOLIUS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software